Navigation Links
Proteonomix Announces a Private Placement of $3.8 Million
Date:3/6/2012

Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements" by words such as "may," will," "should," "expects," "plans,""targets," "believes," "anticipates," "estimates," "predicts," "potential," or "continue," or the negative of those words or comparable words. These forward looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated.  Further information regarding these and other risks is described from time to time in the Company's filings with the SEC, which are available on its website at: http://www.sec.gov. We assume no obligation to update or alter our forward- looking statements made in this release or in any periodic report filed by us under the Securities Exchange A
'/>"/>

SOURCE Proteonomix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
2. ARUP Laboratories Announces Creation of Business Innovations Division
3. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
4. Regeneron Announces March 2012 Investor Conference Presentations
5. MiMedx Group Announces 2011 Results
6. Pro-Dex, Inc. Announces the Sale Of Its Motor Business
7. PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
8. Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program
9. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
10. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
11. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 This report is a ... industry. For an overview analysis, the report introduces ... chain structure, industry overview, policy analysis, and news ... has witnessed rapid development with key manufacturers ... This report mentions quartz tubing upstream raw materials ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... SCOTTSDALE, Ariz., Sept. 14 CHS, an inVentiv,Health company ... U.S. Department,of Defense as a recipient of the 2007 ... by the National Committee of Employer,Support of the National ... America,s employers who provide support to their employees,serving in ...
... SOUTH SAN FRANCISCO, Calif., Sept. 14 ,Exelixis, ... the company has,submitted a comprehensive data report relating ... 2007, GSK requested to initiate its review of,XL880 ... the,product development and commercialization agreement between the two,companies. ...
... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ... Lim, MD, Halozyme,s President and Chief Executive Officer,will present ... be held at,the Grand Hyatt Hotel in New York ... (6:00 a.m. Pacific time). Interested parties can access ...
Cached Biology Technology:CHS Receives Prestigious Honor from Department of Defense 2CHS Receives Prestigious Honor from Department of Defense 3Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference 2
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... COLUMBUS, Ohio The wasting disease associated with some ... also cause significant damage to the heart, new research ... muscle wasting and dramatic weight loss, was believed to ... showed that the condition reduces heart function and changes ...
... pathogens that were once thought to be very different ... are not only similar but also suggest that in ... according to a review published this week in the ... used by bacterial and fungal species to promote genetic ...
... The National Institute of General Medical Sciences has awarded ... for a study titled "Expression Genetics in Drug Therapy." The ... and reduce the number of adverse drug reactions among patients ... State as a member of a nationwide Pharmacogenomics Research Network ...
Cached Biology News:Muscle wasting in cancer does not spare the heart 2Muscle wasting in cancer does not spare the heart 3Linking microbial sex and virulence 2$9.1 million grant to improve drug therapy using gene profiles 2$9.1 million grant to improve drug therapy using gene profiles 3
... targets including proteins and to their modification ... antigens. A&Gs service is divided into ... 40 days (duration may vary slightly dependent ... I: Immunization, test bleed and fusion; $2,500 ...
... Synthetic peptide derived from the N-terminal ... 17 open reading frame 37 (C17orf37 protein) ... C35 protein. On Western blots it identifies ... Reactivity: Human (positive control: full-length human ...
... Two separate vials containing 200 ... same sequence used as antigens for ... 160890) To be ... cyclase polyclonal antiserum (Catalog No. 160890) ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: